NCT01086319View on ClinicalTrials.gov

Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

CompletedOBSERVATIONAL
Enrollment

113,505

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Diabetes Mellitus, Type 2
Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

University of Pennsylvania

OTHER

lead

AstraZeneca

INDUSTRY